Boston Scientific Settles More Stent Patent Suits With J&J, For $1.7 Billion
This article was originally published in The Gray Sheet
Executive Summary
The stent patent disarmament trend continued last week with the biggest settlement yet: Boston Scientific agreed Feb. 1 to pay Johnson & Johnson/Cordis $1.725 billion to settle three disputes dating back to 2003
You may also be interested in...
News In Brief
SCAI’s cath lab quality initiative
News In Brief
SCAI’s cath lab quality initiative
Medtronic, Abbott Settle Longstanding Stent IP Battles For $400 Mil.
Medtronic will pay Abbott Laboratories $400 million to resolve a costly series of global stent patent battles that have dragged on since the '90s and in some cases limited the companies' ability to commercialize in certain markets